

COMPANY OVERVIEW

BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Designed to address alcoholism and certain opioid addictions, the Beat Addiction Recovery Program is used by independent treatment centers or physicians in the United States. The program consists of BioCorRx's proprietary cognitive behavioral therapy (CBT) program and peer recovery support mobile application and may include the use of certain medications typically used for the treatment of substance use disorder (SUD). Which medication used, if any, is at the sole discretion of the treating physician in consultation with their patient. The most common medication used in the program is naltrexone in various forms (oral, injectable, implantable pellet). The company does not sell, manufacture, or compound any drugs or pharmaceuticals. The company also has a pharmaceutical subsidiary, BioCorRx Pharmaceuticals, which is developing medications for future regulatory approval. It's lead candidate is a biodegradable implantable naltrexone pellet for alcohol and opioid use disorders.

MANAGEMENT TEAM

Lourdes Felix

CEO, CFO, and Director

Louis Lucido

President & Director

Dr. Joseph DeSanto

Medical Director Consultant

Dr. John DombrowskiMedical Director Consultant

Dr. George FallierasMedical Director Consultant

RECENT NEWS

BioCorRx Reports 3,985% Revenue Growth to \$313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales

Aug 14 2025, 2:32 PM EDT

BioCorRx Reports Business Update for the First Quarter of 2025 May 20 2025, 8:12 AM EDT

BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC

Mar 10 2025, 8:38 AM EDT

BIOCORRX, INC.

2390 E. Orangewood Ave. Suite 570 Anaheim, CA 92806

STOCK OVERVIEW

Symbol BICX

Exchange OTCQB

Market Cap 8.47m

Last Price \$0.448

52-Week Range \$0.1995 - \$1.45

11/14/2025 02:30 PM EST

INVESTOR RELATIONS

Crescendo Communications, LLC T: 212-671-1020 x304

bicx@crescendo-ir.com

investors@biocorrx.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.